University Hospital Augsburg

Running trials

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Nationwide Children's Hospital· Source

• Not yet recruiting

  New diagnostic pathway in primary diagnosis of clinically significant prostate cancer adding PSMA-PET to mpMRI

  2026-527906-19-00· Phase 2· Klinikum der Technischen Universitaet Muenchen (TUM Klinikum)· Source

• Not yet recruiting

  A clinical trial to learn more about the effects of AAA817 given with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer

  2024-512340-32-01· Phase 3· Novartis Pharma AG· Source

• Not yet recruiting

  Post-intervention dual antiplatelet therapy for mild stroke

  2026-525681-22-00· Phase 3· Technische Universitaet Dresden· Source

• Not yet recruiting

  Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients - NB2015-LR

  2024-517295-37-00· Phase 3· University Of Cologne· Source

• Not yet recruiting

  PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%

  NCT07877584· Phase 3· German Cancer Research Center· Source

• Not yet recruiting

  A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis

  NCT07873801· Phase 3· Almirall, S.A.· Source

• Not yet recruiting

  Continuous or Intermittent Cetuximab Plus FOLFIRI as First-line Treatment in RAS/BRAF Wild-type mCRC Patients

  NCT07004413· Phase 3· Charite University, Berlin, Germany· Source

• Not yet recruiting

  AIEOP-BFM ALL 2025 - International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

  2025-522190-11-01· Phase 3· Universitaetsklinikum Schleswig-Holstein AöR· Source

• Not yet recruiting

  REtrieval of Transurethrally Resected Intact En-bloc Vesical Tumors Using a Retrieval Device for Bladder Tumors

  NCT07762820· Ludwig-Maximilians - University of Munich· Source

• Not yet recruiting

  NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

  NCT07178730· Phase 3· Women's Cancer Study Group GmbH· Source

• Recruiting

  A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma

  NCT05314998· Phase 3· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials

  2024-519638-22-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Gustabor Phase 2 - Treating Taste Changes During Cancer Therapy: A Randomized Study Evaluating an AI- Based Nutrition Intervention

  NCT07649681· Wuerzburg University Hospital· Source

• Not yet recruiting

  GMMG-HD11/DSMM XXI/64007957MMY3010

  NCT07671287· Phase 3· University of Heidelberg Medical Center· Source

• Recruiting

  Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

  NCT07555938· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)

  2025-521390-14-00· Phase 2· Pediatric Research International GmbH· Source

• Recruiting

  Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE)

  2024-516896-34-00· Phase 1/2· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons

  NCT07788729· University of Regensburg· Source

• Recruiting

  A Phase 3 Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children with Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders

  2025-523079-44-00· Phase 3· Ascendis Pharma Endocrinology Division A/S· Source

• Recruiting

  A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034)

  NCT07489495· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Improved Management of Patients With Recent-Onset Stable Chest Pain

  NCT07476040· Philipps University Marburg· Source

• Recruiting

  Local Tenecteplase ApplicatiOn subsequent to endovasCular Recanalization in Anterior CircuLation Stroke - the LOCAL trial

  2024-516544-26-00· Phase 2· Universitaetsklinikum Heidelberg AöR· Source

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

• Recruiting

  Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants

  2025-521762-99-00· Phase 3· University Medical Center Hamburg-Eppendorf· Source

• Recruiting

  Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

  NCT07431281· Phase 3· AstraZeneca· Source

• Recruiting

  Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

  NCT07441395· Phase 2· Corvus Pharmaceuticals, Inc.· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Registry and clinical trial comparing standard intensity and reduced intensity treatment in patients with AML or CLL who do not have residual disease.

  2024-512503-39-00· Phase 4· Medizinische Hochschule Hannover· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source

• Recruiting

  A Phase 1 Study of the Safety and Preliminary Efficacy of CTX112 in Adult Subjects With Refractory Autoimmune Disease.

  2024-518528-54-00· Phase 1· CRISPR Therapeutics AG· Source

• Recruiting

  SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

  NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source

• Recruiting

  Study to Collect Real-world Performance and Safety Data on Penumbra System® in Population With Acute Ischemic Stroke (AIS).

  NCT07107022· Penumbra Inc.· Source

• Recruiting

  Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

  NCT07197307· Phase 2· Universität Münster· Source

• Recruiting

  – IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases

  2024-519929-38-00· Phase 2· Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH· Source

• Recruiting

  Intervention With Tralokinumab in Patients With Moderate-to-severe Atopic Dermatitis With Genital Impact

  NCT07444801· University Hospital Schleswig-Holstein· Source

• Active, not recruiting

  A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa

  2025-520564-17-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Recruiting

  A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis

  2024-519795-11-00· Phase 2· Apogee Therapeutics Inc.· Source

• Recruiting

  HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

  NCT05745714· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

  NCT05751044· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

  NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source

• Recruiting

  A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

  NCT06952803· Phase 3· AstraZeneca· Source

• Recruiting

  Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT)

  2025-521051-23-00· Phase 2· Universitaet Muenster· Source

• Recruiting

  A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

  NCT06911502· Phase 3· Celgene· Source

• Recruiting

  VyClo ITCC-092

  2023-508050-26-00· Phase 1· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source

• Recruiting

  Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

  NCT05690048· Phase 2· Michael Dill· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis

  NCT07037901· Phase 2· Inmagene LLC· Source

• Recruiting

  Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2

  NCT07227246· Phase 3· Joseph Broderick, MD· Source

• Recruiting

  Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

  NCT06696183· Phase 2· Technische Universität Dresden· Source

Showing 50 of 156.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers28 recruiting
• Acute lymphoblastic leukaemia10 recruiting
• Prostate cancer9 recruiting
• Lung cancer8 recruiting
• Colorectal cancer6 recruiting
• Stroke6 recruiting
• Acute myeloid leukaemia5 recruiting
• Atopic dermatitis (eczema)5 recruiting
• Liver and biliary tract cancer5 recruiting
• Multiple myeloma5 recruiting
• Chronic lymphocytic leukaemia4 recruiting
• Diffuse large B-cell lymphoma4 recruiting
• Follicular lymphoma4 recruiting
• Melanoma3 recruiting
• Sarcoma3 recruiting
• Triple-negative breast cancer3 recruiting
• Aortic aneurysm2 recruiting
• Atrial fibrillation2 recruiting
• Chronic myeloid leukaemia2 recruiting
• Coronary artery disease2 recruiting
• Crohn's disease2 recruiting
• Endometrial cancer2 recruiting
• Gastric and oesophageal cancer2 recruiting
• Ovarian cancer2 recruiting
• Type 1 diabetes2 recruiting
• Aortic stenosis1 recruiting
• Barrett's oesophagus1 recruiting
• Bladder cancer1 recruiting
• Brain aneurysm1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Head and neck cancer1 recruiting
• Hodgkin lymphoma1 recruiting
• IgA nephropathy1 recruiting
• Kidney cancer1 recruiting
• Lupus (SLE)1 recruiting
• Metastatic breast cancer1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroblastoma1 recruiting
• Pancreatic cancer1 recruiting
• Systemic sclerosis (scleroderma)1 recruiting
• Turner syndrome1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Immutep S.A.S.· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  Iberdomide vs. Iberdomide Plus Isatuximab Maintenance Therapy Post ASCT in Newly Diagnosed Multiple Myeloma

  NCT06216158· Phase 3· University of Heidelberg Medical Center· Source

• Completed

  A Study to Evaluate Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants with Relapsed or Refractory Multiple Myeloma

  2023-503689-21-00· Phase 1/2· F. Hoffmann-La Roche AG· Source

• Completed

  A MULTICENTER OPEN LABEL 3 MONTH SAFETY STUDY WITH TRADIPITANT IN PATIENTS WITH IDIOPATHIC OR DIABETIC GASTROPARESIS

  2023-503802-35-00· Phase 3· Vanda Pharmaceuticals Inc.· Source

• Completed

  The PEERLESS II Study

  NCT06055920· Inari Medical· Source

• Completed

  Efficacy and Tolerability of AP707 in Patients with chronic Pain due to Diabetic Polyneuropathy

  2022-500897-32-00· Phase 3· Cannaxan GmbH· Source

• Completed

  A Phase 3b, Open-label Study to Evaluate the Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis

  2023-505558-16-00· Phase 3· Almirall S.A.· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Completed

  Magrolimab plus intensive chemotherapy in newly diagnosed “ELN intermediate or poor-risk” AML patients intended to undergo allogeneic stem cell transplantation, a Phase 2, Single-arm, Open-Label Study (MAGROLIC)

  2022-502040-13-00· Phase 2· University of Leipzig· Source

• Completed

  Phase II, multi‑cohort trial of neoadjuvant and post‑surgery IO102‑IO103 and pembrolizumab in patients with selected resectable tumors

  2022-502787-20-00· Phase 2· IO Biotech ApS· Source

• Completed

  A Trial to Evaluate the Efficacy and Safety of Different Doses of LEO 138559 in Adults With Moderate-to-severe Atopic Dermatitis

  NCT05923099· Phase 2· LEO Pharma· Source

• Terminated

  Holmium-166 Transarterial Radioembolization in Unresectable, Early Stage Hepatocellular Carcinoma.

  NCT05451862· Terumo Europe N.V.· Source

• Completed

  A Study of CDX-0159 in Patients With Eosinophilic Esophagitis

  NCT05774184· Phase 2· Celldex Therapeutics· Source

• Completed

  Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial Occlusions

  NCT05499832· Phase 3· Insel Gruppe AG, University Hospital Bern· Source

• Completed

  Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma after first-line therapy (AlloRelapseMMStudy)

  NCT05675319· Phase 3· University Medical Center Hamburg-Eppendorf· Source

• Completed

  EFFICACY AND SAFETY TRIAL OF EPCORITAMAB WITH OR WITHOUT LENALIDOMIDE AS FIRST LINE THERAPY FOR SUBJECTS WITH DIFFUSE LARGE B-CELL LYMPHOMA.

  2023-504832-16-00· Phase 2· Genmab A/S· Source

• Completed

  Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis

  NCT05184088· Phase 3· Lantheus Germany GmbH· Source

• Completed

  Different Doses of Naronapride vs. Placebo in Gastroparesis

  NCT05621811· Phase 2· Dr. Falk Pharma GmbH· Source

• Completed

  PEARLDIFER - A Phase II study of pemigatinib after curative local therapy in locally advanced intrahepatic cholangiocarcinoma (iCCA) harboring FGFR2 fusions/rearrangements

  NCT05565794· Phase 2· Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH· Source

• Completed

  Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial

  NCT05172206· Schön Klinik Berchtesgadener Land· Source

• Active, not recruiting

  IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18)

  NCT05155254· Phase 3· IO Biotech· Source

• Completed

  Pembrolizumab and Lenvatinib in Patients With Advanced HCC Who Are Refractory to Atezolizumab and Bevacizumab/ IO-based Therapy

  NCT05101629· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered

  NCT05182255· Cook Research Incorporated· Source

• Completed

  Tiotropium in preventing preschool asthma (TIPP)

  2024-513916-84-00· Phase 3· Goethe University Frankfurt· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  Coating to Optimize Aneurysm Treatment In The New Flow Diverter Generation

  NCT04870047· Phenox GmbH· Source

• Completed

  A Multicenter, Randomized, Double Blind, Parallel Group Study to Assess the Efficacy and Safety of Oral Etrasimod as Induction and Maintenance Therapy for Moderately to Severely Active Crohn’s Disease

  2024-513569-38-00· Phase 2/3· Arena Pharmaceuticals Inc.· Source

• Active, not recruiting

  Once Daily Versus Twice Daily Budesonide Orodispersible Tablets for Induction of Remission in EoE

  NCT06596252· Phase 3· Dr. Falk Pharma GmbH· Source

• Completed

  Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1)

  NCT04797780· Phase 3· Syros Pharmaceuticals Inc.· Source

• Active, not recruiting

  Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

  NCT04598893· Phase 3· Provention Bio, a Sanofi Company· Source

• Completed

  Clinical Safety Study on 5-Aminolevulinic Acid (5-ALA) in Children and Adolescents With Brain Tumors

  NCT04738162· Phase 2· Universität Münster· Source

• Completed

  Open Label 2-Arm Study of Venetoclax in Combination with Azacitidine Versus Best Supportive Care after Allogeneic Stem Cell Transplantation in Subjects with Acute Myeloid Leukemia (AML)

  NCT04161885· Phase 3· AbbVie Deutschland GmbH & Co. KG· Source

• Completed

  Investigating the Combination of VB10.16 and Atezolizumab in Patients With HPV 16-positive Cervical Cancer

  NCT04405349· Phase 2· Nykode Therapeutics ASA· Source

• Completed

  Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)

  NCT04330820· Phase 1/2· Technische Universität Dresden· Source

• Completed

  Study on the prevention of atopic dermatitis symptoms in children with a high risk of the disease through the regular use of a moisturizing skin cream

  2024-513289-21-00· Phase 3· INFECTOPHARM Arzneimittel und Consilium GmbH· Source

• Completed

  CIRCULATE

  NCT04089631· Phase 3· Technische Universitat Dresden· Source

• Active, not recruiting

  Pediatric Long-Term Follow-up and Rollover Study

  NCT03975829· Phase 4· Novartis Pharmaceuticals· Source

• Active, not recruiting

  Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

  NCT04238637· Phase 2· Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest· Source

• Completed

  PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation

  NCT03996772· Phase 3· Imperial College London· Source

• Completed

  EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

  NCT03594110· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

  NCT03468426· Phase 1· Boehringer Ingelheim· Source

• Completed

  MIND: Artemis in the Removal of Intracerebral Hemorrhage

  NCT03342664· Penumbra Inc.· Source

• Completed

  A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma

  NCT03332017· Phase 2· BeiGene· Source

• Completed

  autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma – a randomized European MCL Network trial

  2024-511235-10-00· Phase 3· Klinikum der Universitaet Muenchen AöR· Source

• Completed

  HD21

  NCT02661503· Phase 3· University Of Cologne· Source

• Completed

  Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)

  NCT02283853· Phase 3· Biogen· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Atopic dermatitis (eczema)30 works · 11 trials
• Barrett's oesophagus5 works · 1 trial